GlyTherix Ltd (“GlyTherix”), an Australian immune-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May...
The poster presentation highlights the preclinical evaluation of several of Adcendo´s ADC candidates for the treatment of osteosarcoma Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of...
Building the team with experienced biotech experts and renowned leaders in the ADC fieldUnderscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the...
